Mirati Therapeutics, Inc. Common Stock
MRTX
MRTX was delisted on the 22nd of January, 2024.
245 hedge funds and large institutions have $8.55B invested in Mirati Therapeutics, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 88 increasing their positions, 91 reducing their positions, and 52 closing their positions.
139% more call options, than puts
Call options by funds: $97.2M | Put options by funds: $40.7M
9% more funds holding in top 10
Funds holding in top 10: 11 → 12 (+1)
3% less repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 91
6% less funds holding
Funds holding: 260 → 245 (-15)
7% less capital invested
Capital invested by funds: $9.15B → $8.55B (-$601M)
25% less first-time investments, than exits
New positions opened: 39 | Existing positions closed: 52
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$147M |
| 2 |
Holocene Advisors
New York
|
+$66.5M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$62.5M |
| 4 |
Millennium Management
New York
|
+$59.4M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$53.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$248M |
| 2 |
JP Morgan Chase
New York
|
-$49M |
| 3 |
PA
Perceptive Advisors
New York
|
-$46.3M |
| 4 |
CCM
Consonance Capital Management
New York
|
-$43.7M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$42.2M |
MRTX Hedge Fund Activity: Q2 2021 in Review
245 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Mirati Therapeutics, Inc. Common Stock (MRTX) for Q2 2021, worth a combined $8.55B — down 6.6% from $9.15B a quarter earlier.
Sellers outnumbered buyers: 52 funds closed out of MRTX and 39 opened new positions — a net loss of 13 holders — while 91 trimmed existing stakes and 88 added.
The largest buyer was Wellington Management Group, adding an estimated $147M. The largest seller was BlackRock, cutting an estimated $248M.
- 245 institutional investors held Mirati Therapeutics, Inc. Common Stock (MRTX) as of Q2 2021, down from 260 in Q1 2021.
- Funds reported $8.55B of Mirati Therapeutics, Inc. Common Stock stock for Q2 2021, down 6.6% quarter-over-quarter.
- 39 funds opened new Mirati Therapeutics, Inc. Common Stock positions in Q2 2021 and 52 closed out, a net change of -13 holders.
- The largest Mirati Therapeutics, Inc. Common Stock buyer in Q2 2021 was Wellington Management Group, an estimated $147M added.
- The largest Mirati Therapeutics, Inc. Common Stock seller in Q2 2021 was BlackRock, an estimated $248M sold.
Based on aggregated 13F filings for Q2 2021.